Why Rheumatologists Get Sued: The Weekly Methotrexate, the Missed Giant Cell Arteritis, and the Immunosuppressed Infection

By John Mahoney · June 2026 · 8 min read

Rheumatology is a low-volume specialty for malpractice claims, but the claims that come are rarely about a single missed reading on a single day. They are about medications that are dangerous by design, monitoring that has to run for years, and a small set of emergencies where hours decide whether harm is reversible. A rheumatologist manages immunosuppressants that can cause fatal marrow failure if dosed wrong, hands patients drugs that switch off the immune system, and is the last line of defense against conditions like giant cell arteritis that blind permanently when missed. An attorney who screens these files like a typical missed-diagnosis case will overlook the dosing and monitoring failures where the real liability lives. This guide explains where rheumatology liability actually concentrates, the cannot-miss failures behind it, and what separates a strong case from a weak one — for plaintiff and defense med-mal attorneys.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. The patterns below draw on closed-claims experience, published case reports, and clinical guidance that span different eras and definitions; treat them as directional, verify against the controlling jurisdiction, and value any individual case on its own record.

The Frequency-and-Severity Reality

By frequency, rheumatology sits among the lower-risk specialties. Like most medical (non-surgical, non-procedural) subspecialties, its annual claim frequency runs below the all-specialty average, and rheumatologists make up a small share of physicians and a correspondingly small share of closed claims. Cumulative career risk is still real — most physicians in lower-risk specialties face at least one claim before retirement — but the year-over-year exposure is modest compared with the surgical and obstetric fields.

Severity, however, does not track frequency here, and that is the trap. The defining rheumatology claims are medication-toxicity and missed-emergency cases, and both can be catastrophic: a methotrexate dosing error can kill, and a missed giant cell arteritis blinds irreversibly. These are not modest-value files. When the harm is death from pancytopenia, permanent bilateral blindness, or a disabling infection in an immunosuppressed patient, indemnity is high and the cases are difficult to defend on damages even where standard-of-care arguments exist. The screening lesson is that frequency understates the specialty's risk profile: a single rheumatology file can carry severity far above what the low claim rate would suggest, so the value of each intake has to be assessed on its specific failure, not on a base rate.

The Dominant Allegation Types

Rheumatology claims cluster around the drugs the specialty prescribes and the conditions it is expected to catch:

• Medication error — dosing and toxicity — the signature rheumatology allegation. Methotrexate dosed daily instead of weekly is the catastrophic prototype, alongside other DMARD and biologic toxicity, with allegations of overdose, wrong frequency, and failure to adjust for renal function.
• Failure to monitor / closed-loop lab failure — failure to order, track, or act on the lab surveillance these drugs require (CBC, liver and renal panels), allowing hepatotoxicity and marrow suppression to progress undetected.
• Failure to diagnose or delay in diagnosis — missed giant cell (temporal) arteritis, septic arthritis, and serious organ involvement of lupus or vasculitis, plus malignancy mistaken for autoimmune disease.
• Immunosuppression and infection — failure to screen for latent tuberculosis or hepatitis before starting a biologic, and failure to recognize serious infection in an immunosuppressed patient.
• Lack of informed consent — failure to convey the infection, malignancy, and organ-toxicity risks of immunosuppressant and biologic therapy, central to the medication claims.

The structural point: rheumatology is a pharmacology specialty more than a procedural one. The merit analysis usually lives in the medication order, the monitoring record, and the timing of an emergency diagnosis — not in a single procedure note. Any intake should be triaged first on whether it is a drug-toxicity case, a missed-emergency case, or an infection-in-immunosuppression case, because the experts, the causation chain, and the damages differ sharply across the three.

The Cannot-Miss Conditions and Failures

The conditions and failures that drive rheumatology litigation are:

• Methotrexate dosing catastrophe. The single most dangerous error in the specialty. Methotrexate for rheumatic disease is a weekly drug; taken daily it causes lethal pancytopenia, mucositis, and multi-organ toxicity. The recurring failure is an order, prescription, or counseling that allowed daily dosing, or a failure to catch and reverse it once symptoms appeared.
• DMARD and biologic toxicity without monitoring. Failure to run and act on the required CBC and liver-function surveillance, letting hepatotoxicity, marrow suppression, or other organ toxicity progress — the closed-loop failure in drug form.
• Giant cell (temporal) arteritis — missed or delayed. The must-not-miss diagnosis. Untreated, it causes irreversible blindness; the standard of care is to start high-dose steroids on clinical suspicion before biopsy confirmation. The recurring failure is a headache, jaw claudication, or visual symptom in an older patient that was not recognized and treated in time.
• Septic arthritis and serious organ involvement of lupus or vasculitis — failure to diagnose a joint infection or to recognize renal, CNS, or other organ involvement before permanent damage, where delay drives the harm.
• Infection in the immunosuppressed patient — failure to screen for latent TB or hepatitis before a biologic, and failure to recognize a serious or opportunistic infection in a patient whose immune system the rheumatologist deliberately suppressed.
• Malignancy masquerading as autoimmune disease — anchoring on a rheumatologic label (vasculitis, polymyalgia, inflammatory arthritis) while a cancer producing similar symptoms goes undiagnosed.

For the medication side, the most actionable screening question is the closed-loop question in two parts: was the drug ordered at the correct dose and frequency, and was the mandated lab monitoring ordered, tracked, and acted on? For the emergency side, the decisive question is timing: in a suspected giant cell arteritis, was empiric steroid treatment started before the visual loss became fixed? These cases very often turn on a frequency error or a missed surveillance result rather than a subtle diagnostic judgment.

The Contributing Factors That Drive Payouts

Across rheumatology claims, the recurring contributing factors are:

• Medication management — dose, frequency, and renal adjustment — the most distinctive driver. The weekly-versus-daily methotrexate frequency error is the prototype, alongside failure to dose-adjust DMARDs and biologics for renal function or comorbidity.
• Monitoring and follow-up of laboratory surveillance — the costliest systemic factor: failure to order, receive, track, or act on the CBC and liver and renal panels that immunosuppressant therapy requires. A normal-appearing patient whose marrow or liver was failing on un-reviewed labs is a paid claim waiting to happen.
• Clinical judgment and timeliness in emergencies — failure to recognize giant cell arteritis, septic arthritis, or organ-threatening lupus or vasculitis in time, where the delay rather than the eventual diagnosis is the negligence.
• Pre-treatment screening and infection vigilance — failure to screen for latent TB or hepatitis before a biologic, and failure to lower the threshold for serious infection in an immunosuppressed patient.
• Communication, informed consent, and documentation — incomplete consent for immunosuppressant risks, unclear dosing instructions to the patient, and thin records of monitoring orders and result-notification that weaken the defense.

Two of these are rheumatology-specific levers. The first is the dosing-instruction record: in a daily-methotrexate disaster, the case often turns on what the order, the prescription label, and the documented patient counseling actually said about frequency — and whether the error was caught when toxicity appeared. The second is the monitoring closed loop: in a marrow-suppression or hepatotoxicity claim, the line between a defensible file and a paid claim is usually whether the chart shows the required labs were ordered, reviewed, and acted on. Documentation rarely creates liability in this specialty, but it consistently decides whether a claim is paid.

Strong Case vs. Weak Case in Rheumatology Malpractice

The same factors grade the file, and the framing is useful to both sides.

What makes a rheumatology case strong (plaintiff) / dangerous (defense)

• A methotrexate order, prescription, or counseling that permitted daily rather than weekly dosing, followed by pancytopenia, mucositis, or death — a clean frequency-error chain.
• Required CBC or liver-function monitoring that was never ordered, or results that came back abnormal and were never reviewed or acted on, with marrow suppression or hepatotoxicity progressing on an un-read lab.
• A classic giant cell arteritis presentation — older patient with new headache, jaw claudication, or visual symptoms — where empiric steroids were not started before vision was permanently lost.
• A biologic started without documented latent-TB or hepatitis screening, or a serious infection in an immunosuppressed patient that was not recognized despite presenting warning signs.

What makes a rheumatology case weak (plaintiff) / defensible (defense)

• A correctly written weekly methotrexate order with documented patient counseling on frequency, where a documented patient self-administration error or pharmacy dispensing error broke the chain away from the rheumatologist.
• A complete, timely monitoring record — labs ordered, reviewed, and acted on — with the closed loop intact and any abnormality addressed.
• An atypical or evolving presentation of giant cell arteritis or organ involvement that did not meet the recognized clinical threshold at the time, with appropriate workup documented, framing the outcome as an inherent disease risk rather than negligence.
• Documented pre-biologic screening, informed consent that disclosed the infection and malignancy risks, and a record showing the patient's non-adherence, missed appointments, or declined monitoring drove the harm.

Rheumatology rewards a fast triage to the right model. On the medication side, the case lives or dies on the dosing instruction and the monitoring closed loop. On the emergency side, it turns on timing — whether the must-not-miss giant cell arteritis was treated before the harm became fixed. On the infection side, it turns on pre-treatment screening and the threshold for recognizing infection in a patient who was deliberately immunosuppressed. Whichever side you are on, grading the file means matching the right model to the right claim and pressure-testing the expert who will carry the causation chain.

Bottom Line

Rheumatologists get sued rarely, but the claims that come carry severity well above what the low frequency suggests, because the specialty runs on drugs that are dangerous by design and stands as the last guard against emergencies that disable and blind. The cannot-miss facts are the methotrexate dosed daily instead of weekly, the lab surveillance that was never ordered or never reviewed, the giant cell arteritis treated too late to save vision, and the infection that took hold in a patient whose immune system was switched off without screening. Whether you are screening these cases for the plaintiff or defending them, triage first to the right model — drug toxicity, missed emergency, or infection in immunosuppression — and grade the file on the dosing record, the monitoring closed loop, and the timing of treatment, not on the diagnosis label alone.

Questions? Contact us at [email protected] or (856) 979-6525

🔎 Screening a case in a different specialty? Browse all 70 specialty malpractice-risk guides in one place — Why Doctors Get Sued: Malpractice Risk by Specialty →